These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 8605871)
1. Protein dimerization between Lmo2 (Rbtn2) and Tal1 alters thymocyte development and potentiates T cell tumorigenesis in transgenic mice. Larson RC; Lavenir I; Larson TA; Baer R; Warren AJ; Wadman I; Nottage K; Rabbitts TH EMBO J; 1996 Mar; 15(5):1021-7. PubMed ID: 8605871 [TBL] [Abstract][Full Text] [Related]
2. Chromosomal translocations and leukaemia: a role for LMO2 in T cell acute leukaemia, in transcription and in erythropoiesis. Rabbitts TH; Axelson H; Forster A; Grutz G; Lavenir I; Larson R; Osada H; Valge-Archer V; Wadman I; Warren A Leukemia; 1997 Apr; 11 Suppl 3():271-2. PubMed ID: 9209362 [TBL] [Abstract][Full Text] [Related]
3. A DNA-binding mutant of TAL1 cooperates with LMO2 to cause T cell leukemia in mice. Draheim KM; Hermance N; Yang Y; Arous E; Calvo J; Kelliher MA Oncogene; 2011 Mar; 30(10):1252-60. PubMed ID: 21057528 [TBL] [Abstract][Full Text] [Related]
4. Structure of the leukemia oncogene LMO2: implications for the assembly of a hematopoietic transcription factor complex. El Omari K; Hoosdally SJ; Tuladhar K; Karia D; Vyas P; Patient R; Porcher C; Mancini EJ Blood; 2011 Feb; 117(7):2146-56. PubMed ID: 21076045 [TBL] [Abstract][Full Text] [Related]
5. Identification of the LMO4 gene encoding an interaction partner of the LIM-binding protein LDB1/NLI1: a candidate for displacement by LMO proteins in T cell acute leukaemia. Grutz G; Forster A; Rabbitts TH Oncogene; 1998 Nov; 17(21):2799-803. PubMed ID: 9840944 [TBL] [Abstract][Full Text] [Related]
6. The LIM protein RBTN2 and the basic helix-loop-helix protein TAL1 are present in a complex in erythroid cells. Valge-Archer VE; Osada H; Warren AJ; Forster A; Li J; Baer R; Rabbitts TH Proc Natl Acad Sci U S A; 1994 Aug; 91(18):8617-21. PubMed ID: 8078932 [TBL] [Abstract][Full Text] [Related]
7. Assembly of the oncogenic DNA-binding complex LMO2-Ldb1-TAL1-E12. Ryan DP; Duncan JL; Lee C; Kuchel PW; Matthews JM Proteins; 2008 Mar; 70(4):1461-74. PubMed ID: 17910069 [TBL] [Abstract][Full Text] [Related]
8. V(D)J-mediated translocations in lymphoid neoplasms: a functional assessment of genomic instability by cryptic sites. Marculescu R; Le T; Simon P; Jaeger U; Nadel B J Exp Med; 2002 Jan; 195(1):85-98. PubMed ID: 11781368 [TBL] [Abstract][Full Text] [Related]
9. Lmo2 and Scl/Tal1 convert non-axial mesoderm into haemangioblasts which differentiate into endothelial cells in the absence of Gata1. Gering M; Yamada Y; Rabbitts TH; Patient RK Development; 2003 Dec; 130(25):6187-99. PubMed ID: 14602685 [TBL] [Abstract][Full Text] [Related]
10. Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy. Pike-Overzet K; de Ridder D; Weerkamp F; Baert MR; Verstegen MM; Brugman MH; Howe SJ; Reinders MJ; Thrasher AJ; Wagemaker G; van Dongen JJ; Staal FJ Leukemia; 2007 Apr; 21(4):754-63. PubMed ID: 17268520 [TBL] [Abstract][Full Text] [Related]
11. Transcriptional activity of TAL1 in T cell acute lymphoblastic leukemia (T-ALL) requires RBTN1 or -2 and induces TALLA1, a highly specific tumor marker of T-ALL. Ono Y; Fukuhara N; Yoshie O J Biol Chem; 1997 Feb; 272(7):4576-81. PubMed ID: 9020185 [TBL] [Abstract][Full Text] [Related]
13. The Lmo2 oncogene initiates leukemia in mice by inducing thymocyte self-renewal. McCormack MP; Young LF; Vasudevan S; de Graaf CA; Codrington R; Rabbitts TH; Jane SM; Curtis DJ Science; 2010 Feb; 327(5967):879-83. PubMed ID: 20093438 [TBL] [Abstract][Full Text] [Related]
14. Notch1 inhibition targets the leukemia-initiating cells in a Tal1/Lmo2 mouse model of T-ALL. Tatarek J; Cullion K; Ashworth T; Gerstein R; Aster JC; Kelliher MA Blood; 2011 Aug; 118(6):1579-90. PubMed ID: 21670468 [TBL] [Abstract][Full Text] [Related]
15. The LIM-domain binding protein Ldb1 and its partner LMO2 act as negative regulators of erythroid differentiation. Visvader JE; Mao X; Fujiwara Y; Hahm K; Orkin SH Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13707-12. PubMed ID: 9391090 [TBL] [Abstract][Full Text] [Related]
16. TAL1 and LIM-only proteins synergistically induce retinaldehyde dehydrogenase 2 expression in T-cell acute lymphoblastic leukemia by acting as cofactors for GATA3. Ono Y; Fukuhara N; Yoshie O Mol Cell Biol; 1998 Dec; 18(12):6939-50. PubMed ID: 9819382 [TBL] [Abstract][Full Text] [Related]
17. T cell tumorigenesis in Lmo2 transgenic mice is independent of V-D-J recombinase activity. Drynan LF; Hamilton TL; Rabbitts TH Oncogene; 2001 Jul; 20(32):4412-5. PubMed ID: 11466623 [TBL] [Abstract][Full Text] [Related]
18. Disordered T-cell development and T-cell malignancies in SCL LMO1 double-transgenic mice: parallels with E2A-deficient mice. Chervinsky DS; Zhao XF; Lam DH; Ellsworth M; Gross KW; Aplan PD Mol Cell Biol; 1999 Jul; 19(7):5025-35. PubMed ID: 10373552 [TBL] [Abstract][Full Text] [Related]
19. The LMO2 T-cell oncogene is activated via chromosomal translocations or retroviral insertion during gene therapy but has no mandatory role in normal T-cell development. McCormack MP; Forster A; Drynan L; Pannell R; Rabbitts TH Mol Cell Biol; 2003 Dec; 23(24):9003-13. PubMed ID: 14645513 [TBL] [Abstract][Full Text] [Related]
20. The oncogenic LIM protein Rbtn2 causes thymic developmental aberrations that precede malignancy in transgenic mice. Larson RC; Osada H; Larson TA; Lavenir I; Rabbitts TH Oncogene; 1995 Sep; 11(5):853-62. PubMed ID: 7545805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]